No Data
No Data
Atossa Therapeutics Appoints Heather Rees as Chief Financial Officer
SEATTLE, July 02, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), today announced the appointment of Heather Rees as the Company's new Chief Financial
H.C. Wainwright Maintains Atossa Therapeutics(ATOS.US) With Buy Rating, Maintains Target Price $6
H.C. Wainwright analyst Emily Bodnar maintains $Atossa Therapeutics(ATOS.US)$ with a buy rating, and maintains the target price at $6.According to TipRanks data, the analyst has a success rate of 33.6
Express News | HC Wainwright & Co. Reiterates Buy on Atossa Therapeutics, Maintains $6 Price Target
Express News | Atossa Therapeutics: Data Expected to Further Validate That (Z)-Endoxifen Is Safe & Highly Efficacious in Premenopausal Women Without Need for OFS
Express News | Atossa Therapeutics: Change in Study Dose Was Determined Following a Review of Safety, Efficacy and Pharmacokinetic (Pk) Data
Express News | Atossa Therapeutics: Combination Study Will Now Enroll Approximately 80 Participants Across Two 40-Participant Cohorts